Neoepitope Identification Service

With our cutting-edge cellular technologies and accumulated experience, Creative Biolabs has developed a comprehensive platform for neoantigen-based cancer immunotherapy development.

Introduction of Neoantigen Identification

The neoantigen can stimulate the immune system against cancer, which is not only the key to distinguish between cancer cells and normal cells, but also the most critical "hit" in the development of effective anti-tumor vaccines for immuno-oncology research. Creative Biolabs leverages a unique and comprehensive sequencing portfolio that combines proprietary information algorithms and computational workflow to drive discovery of neoantigens.

Our comprehensive portfolio of neoantigen identification services combines highly accurate neoantigen prediction algorithms with our genomics/genomic sequencing platform technology to optimize the flow of neoantigen assays. It allows us to extend our comprehensive IO service portfolio based on transcriptomics analysis and somatic/germline genomics analysis to facilitate our clients' research projects.

Neoantigen Identification Pipeline

To screen neoantigens with potential immunogenicity, a complete and quick prediction pipeline (see Fig.1a) with sequencing technologies and computational tools has been well developed. To get good tumor-specific and immunogenic neoantigens, the main computational modules commonly applied are listed below:

• Peptide mutation calling with a set of bioinformatic tools could select candidate neoantigens (Fig.1b).
• HLA typing could identify distinct MHC-I peptides for CD8+ T cells or MHC-II peptides for CD4+ T cells (Fig.1c).
• HLA binding prediction could estimate the binding affinity and specificity of candidate neoantigens and HLA alleles (Fig.1d).
• T cell recognition prediction could validate the immunogenicity of neoantigens with the specific HLA allele and TCRs (Fig.1e).

Fig.1 Computational neoantigen prediction pipeline and bioinformatic tools.¹

One-Stop Neoantigen Identification Workflow

Our experienced laboratory professionals focus on your samples from beginning to the results report. and follow strict quality procedures to ensure the accuracy of your results.

Key Benefits

• A one-stop solution from sample processing to candidate neoantigen identification
• Accurate, sensitive and efficient neoantigen algorithms
• Comprehensive data collection
• Extensive experience in sample processing and sequencing

Results Display

Fig.2 Top recurrently mutated genes in EOC patients.2	Fig.3 Measured percentile ranks of HLA alleles.3
Fig.4 Neoantigen prioritization landscape.2	Fig.5 Neoepitope identification.3

Frequently Asked Questions

Q: What anti-tumor strategies could be used based on neoantigen?

A: Neoantigens could be used in bispecific antibody development, TCR-T, CAR-T, DC vaccines, and peptide vaccines. Creative Biolabs has established a professional team for neoantigen-based immunotherapy development.

We are wishing to cooperate with you to develop a revolutionary approach for cancer-based drug discovery. Please for free to contact us for project quotations and more detailed information.

References

1. Xie, Na, et al. "Neoantigens: promising targets for cancer therapy." Signal Transduction and Targeted Therapy 8.1 (2023): 9.
2. Liu, Song, et al. "Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer." Journal for immunotherapy of cancer 7.1 (2019): 1-17.
3. Koşaloğlu-Yalçın, Zeynep, et al. "Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLA-DQ2. 5." Immunology 162.2 (2021): 235-247.

For Research Use Only | Not For Clinical Use